Literature DB >> 15940620

Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study.

Lawrence C T Hung1, Jessica Y L Ching, Joseph J Y Sung, Ka-Fai To, Aric J Hui, Vincent W S Wong, Rupert W L Leong, Henry L Y Chan, Justin C Y Wu, Wai-Keung Leung, Yuk-Tong Lee, S C Sydney Chung, Francis K L Chan.   

Abstract

BACKGROUND & AIMS: Helicobacter pylori-negative idiopathic ulcers are increasingly recognized. The secular trend and long-term outcome of this condition are unknown.
METHODS: We prospectively studied consecutive patients with bleeding gastroduodenal ulcers from January to December 2000. The incidence and etiology of ulcers during this period were compared with that between September 1997 and August 1998. H. pylori-negative idiopathic ulcers were defined as negative tests for H. pylori, no exposure to analgesics within 4 weeks, and absence of other risk factors for ulcers. After the ulcers had healed, patients with H. pylori-negative idiopathic ulcers and patients with H. pylori ulcers who received eradication therapy were followed up for 12 months without anti-ulcer drugs.
RESULTS: Six hundred thirty-eight patients had bleeding ulcers: 213 (33.4%) were H. pylori ulcers, and 120 (18.8%) were H. pylori-negative idiopathic ulcers (vs 480 [50.3%] H. pylori ulcers and 40 [4.2%] H. pylori-negative idiopathic ulcers in 1997-1998; P < .001). H. pylori-negative idiopathic ulcers accounted for 16.1% of patients who were admitted for bleeding and 42.4% of patients who bled while in the hospital (P < .0001); 28.3% of patients with H. pylori-negative idiopathic ulcers had histologic evidence of past H. pylori infection. The probability of recurrent ulcer complications in 12 months was 13.4% (95% CI: 7.3%-19.5%) in patients with H. pylori-negative idiopathic ulcers and 2.5% (95% CI: 0.4%-4.6%) in patients with H. pylori ulcers who received eradication therapy (P = .0002).
CONCLUSIONS: The incidence of H. pylori-negative idiopathic bleeding ulcers is rising. These ulcers are prone to recurrent complications.

Entities:  

Mesh:

Year:  2005        PMID: 15940620     DOI: 10.1053/j.gastro.2005.03.026

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  25 in total

1.  Changing prevalence of Helicobacter pylori infection and peptic ulcer among dyspeptic patients.

Authors:  Dino Vaira
Journal:  Intern Emerg Med       Date:  2015-09-09       Impact factor: 3.397

2.  Helicobacter pylori negative, non-steroidal anti-inflammatory drug-negative peptic ulcers in India.

Authors:  Mahesh Kumar Goenka; Shounak Majumder; Pradeepta Kumar Sethy; Madhurima Chakraborty
Journal:  Indian J Gastroenterol       Date:  2011-03-22

Review 3.  Molecular mechanisms in therapy of acid-related diseases.

Authors:  J M Shin; O Vagin; K Munson; M Kidd; I M Modlin; G Sachs
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

4.  The influence of etiologic factors on clinical outcome in patients with peptic ulcer bleeding.

Authors:  Neven Ljubičić; Zeljko Puljiz; Ivan Budimir; Alen Bišćanin; Andre Bratanić; Tajana Pavić; Marko Nikolić; Davor Hrabar; Vladimir Supanc
Journal:  Dig Dis Sci       Date:  2012-06-27       Impact factor: 3.199

5.  Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan.

Authors:  Kae Sugawara; Shigeto Koizumi; Yohei Horikawa; Nobuya Mimori; Tsuyotoshi Tsuji; Hajime Ishii; Shusei Fujimori; Kengo Onochi; Hiroyuki Watanabe; Katsunori Iijima
Journal:  J Gastroenterol       Date:  2019-04-29       Impact factor: 7.527

Review 6.  Optimal management of peptic ulcer disease in the elderly.

Authors:  Alberto Pilotto; Marilisa Franceschi; Stefania Maggi; Filomena Addante; Daniele Sancarlo
Journal:  Drugs Aging       Date:  2010-07-01       Impact factor: 3.923

7.  Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.

Authors:  Hsiu-Chi Cheng; Bor-Shyang Sheu
Journal:  World J Gastrointest Endosc       Date:  2011-03-16

Review 8.  Helicobacter pylori-negative, non-steroidal anti-inflammatory drug: negative idiopathic ulcers in Asia.

Authors:  Katsunori Iijima; Takeshi Kanno; Tomoyuki Koike; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

9.  Clinical characteristics of Helicobacter pylori-negative drug-negative peptic ulcer bleeding.

Authors:  Woo Chul Chung; Eun Jung Jeon; Dae Bum Kim; Hea Jung Sung; Yeon-Ji Kim; Eun Sun Lim; Min-Ah Kim; Jung Hwan Oh
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

10.  Increasing biopsy number and sampling from gastric body improve the sensitivity of rapid urease test in patients with peptic ulcer bleeding.

Authors:  Tzong-Hsi Lee; Chien-Chu Lin; Chen-Shuan Chung; Cheng-Kuan Lin; Cheng-Chao Liang; Kuang-Chau Tsai
Journal:  Dig Dis Sci       Date:  2014-09-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.